CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 130 target
Drug / intervention
Magnesium sulfate +1 moredrug
Likely dose
Not stated in record
Key inclusion· 1
  • ✓Adults ≥18 years old with malignant mesothelioma undergoing surgery with HIOC
Key exclusion· 11
  • ✕eGFR <45 ml/min/1.73m2 or end-stage kidney disease on renal replacement therapy
  • ✕Serum magnesium >3 mg/dl
  • ✕Pregnant or breastfeeding
  • ✕Neuromuscular disease (myasthenia gravis, ALS, multiple sclerosis, muscular dystrophy, myositis)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05730816
NCT05730816Phase 2RecruitingOn TrackUpdated 7mo ago
Long Recruiting
CompareCT.gov

MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI

Brigham and Women's Hospital·interventional·Posted Feb 16, 2023·Updated Nov 21, 2025

In Brief

A Phase 2 clinical trial evaluating Magnesium sulfate and Normal Saline for Mesothelioma. Currently recruiting, targeting 130 participants across 1 site.

Detailed Summary

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2Recruiting
202320242025202620272028
First PostedFeb 16, 2023
Enrollment StartApr 4, 2023
Primary CompletionApr 3, 2027
Study CompletionJan 1, 2028
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 3.4 years agoPrimary completion in 9 months

Interventions

Magnesium sulfatedrug

Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.

Normal Salinedrug

Intravenous infusion of normal saline.